Fig. 4: Oral reovirus suppresses tumor growth by inducing tumor-specific CD8⁺ T cells.

A–F Mice were subcutaneously implanted with CT26 tumor cells and treated orally with PBS or RC402. A, B Representative images and comparisons of CD8⁺ T cells, CD31⁺ tumor vasculatures, granzyme B (GzB)⁺ T cells, and caspase 3 (Casp3)⁺ apoptotic cells within tumor tissues (n = 5 per group). C, D Comparison of CD8⁺ T cells and CD4⁺ T cells in tumors (n = 5 per group). E Comparisons of CD4⁺Foxp3⁺CD25⁺ Tregs (n = 5 per group). F Comparison of the AH-1 tetramer⁺ CD8⁺ T cells (n = 4 per group, one-tailed Student’s t test). G MC38 tumor cells were subcutaneously implanted into wild-type (WT) (n = 7), Batf3 knockout (KO) (n = 6), and αIFNAR-1-treated WT mice (n = 7), and the mice were treated with PBS, IT, or oral RC402.Comparisons of tumor growth. H Nude mice were subcutaneously implanted with CT26 tumor cells and treated with PBS, IT, or oral RC402. Comparisons of tumor growth (n = 9 for IT PBS; n = 8 for IT RC402; n = 9 for oral PBS; n = 8 for oral RC402). I Mice were subcutaneously implanted with CT26 tumor cells and treated with oral RC402 and depleting antibodies for CD8⁺ T cells (αCD8) or CD4⁺ T cells (αCD4) (n = 5 per group). Comparisons of tumor growth. Data are pooled from two independent experiments. Values are expressed as the mean ± SD. Unless otherwise denoted, two-tailed Student’s t test and ANOVA with Tukey post-hoc test were used. Scale bars, 100 μm. Source data are provided as a Source Data file.